

ICMJE DISCLOSURE FORM

Date: Feb 6th, 2024
 Your Name: Shiting Xu
 Manuscript Title: Hyperprogressive disease under anti-PD-1 rechallenge after a favorable response to initial anti-PD-1 treatment for non-small cell lung cancer: a case report
 Manuscript number (if known): TLCR-23-765-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> </u> None	
6	Payment for expert testimony	<u> </u> None	
7	Support for attending meetings and/or travel	<u> </u> None	
8	Patents planned, issued or pending	<u> </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> </u> None	
11	Stock or stock options	<u> </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> </u> None	
13	Other financial or non-financial interests	<u> </u> None	

Please summarize the above conflict of interest in the following box:

None

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Feb 20 th , 2024

Your Name: Takehito Shukuya

Manuscript Title: Hyperprogressive disease under anti-PD-1 rechallenge after a favorable response to initial anti-PD-1 treatment for non-small cell lung cancer: a case report

Manuscript number (if known): TLCR-23-765-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the **current manuscript only**.

The author’s relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	AstraZeneca	
		Chugai Pharmaceutical	
		Boehringer Ingelheim	
		Novartis	
		MSD	
3	Royalties or licenses	<input checked="" type="checkbox"/> None	

4	Consulting fees	<input checked="" type="checkbox"/> None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	AstraZeneca	
		Chugai Pharmaceutical	
		Boehringer Ingelheim	
		Novartis	
		MSD	
		Taiho Pharma	
		Daiichi-Sankyo	
		Ono Pharmaceutical	
		Bristol-Myers Squibb	
		Nippon Kayaku	
		Pfizer	
		Takeda	
		Eli Lilly and Company	
		AMGEN	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

Takehito Shukuya received grants from AstraZeneca, Chugai Pharmaceutical, Boehringer Ingelheim, Novartis, MSD and payment or honoraria for lectures, presentations, speaker bureaus from AstraZeneca, Chugai Pharmaceutical, Boehringer Ingelheim, Novartis, MSD, Taiho Pharma, Daiichi-Sankyo, Ono Pharmaceutical, Bristol-Myers Squibb, Nippon Kayaku, Pfizer, Takeda, Eli Lilly and Company, AMGEN.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Feb 6th, 2024
 Your Name: Shoko Shimamura
 Manuscript Title: Hyperprogressive disease under anti-PD-1 rechallenge after a favorable response to initial anti-PD-1 treatment for non-small cell lung cancer: a case report
 Manuscript number (if known): TLCR-23-765-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input type="radio"/> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="radio"/> None	
3	Royalties or licenses	<input type="radio"/> None	
4	Consulting fees	<input type="radio"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="radio"/> None	
6	Payment for expert testimony	<input type="radio"/> None	
7	Support for attending meetings and/or travel	<input type="radio"/> None	
8	Patents planned, issued or pending	<input type="radio"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="radio"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="radio"/> None	
11	Stock or stock options	<input type="radio"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="radio"/> None	
13	Other financial or non-financial interests	<input type="radio"/> None	

Please summarize the above conflict of interest in the following box:

None

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Feb 12th, 2024

Your Name: TAKUO HAYASHI

Manuscript Title: Hyperprogressive disease under anti-PD-1 rechallenge after a favorable response to initial anti-PD-1 treatment for non-small cell lung cancer: a case report

Manuscript number (if known): TLCR-23-765-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> </u> None	
6	Payment for expert testimony	<u> </u> None	
7	Support for attending meetings and/or travel	<u> </u> None	
8	Patents planned, issued or pending	<u> </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> </u> None	
11	Stock or stock options	<u> </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> </u> None	
13	Other financial or non-financial interests	<u> </u> None	

Please summarize the above conflict of interest in the following box:

There is no conflict of interest to disclose.

Please place an "X" next to the following statement to indicate your agreement:

 X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Feb 6th, 2024

Your Name: Yoshihiko Sato

Manuscript Title: Hyperprogressive disease under anti-PD-1 rechallenge after a favorable response to initial anti-PD-1 treatment for non-small cell lung cancer: a case report

Manuscript number (if known): TLCR-23-765-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> </u> None	
6	Payment for expert testimony	<u> </u> None	
7	Support for attending meetings and/or travel	<u> </u> None	
8	Patents planned, issued or pending	<u> </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> </u> None	
11	Stock or stock options	<u> </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> </u> None	
13	Other financial or non-financial interests	<u> </u> None	

Please summarize the above conflict of interest in the following box:

No COI

Please place an "X" next to the following statement to indicate your agreement:

 X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Feb 12th, 2024
 Your Name: Hitomi Shiozaki
 Manuscript Title: Hyperprogressive disease under anti-PD-1 rechallenge after a favorable response to initial anti-PD-1 treatment for non-small cell lung cancer: a case report
 Manuscript number (if known): TLCR-23-765-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> </u> None	
6	Payment for expert testimony	<u> </u> None	
7	Support for attending meetings and/or travel	<u> </u> None	
8	Patents planned, issued or pending	<u> </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> </u> None	
11	Stock or stock options	<u> </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> </u> None	
13	Other financial or non-financial interests	<u> </u> None	

Please summarize the above conflict of interest in the following box:

None

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Feb 12th, 2024

Your Name: Toshihiko Nishioki

Manuscript Title: Hyperprogressive disease under anti-PD-1 rechallenge after a favorable response to initial anti-PD-1 treatment for non-small cell lung cancer: a case report

Manuscript number (if known): TLCR-23-765-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> </u> None	
6	Payment for expert testimony	<u> </u> None	
7	Support for attending meetings and/or travel	<u> </u> None	
8	Patents planned, issued or pending	<u> </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> </u> None	
11	Stock or stock options	<u> </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> </u> None	
13	Other financial or non-financial interests	<u> </u> None	

Please summarize the above conflict of interest in the following box:

I declare no conflicts of interest associated with this manuscript.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Feb 6th, 2024
 Your Name: Koichi Nishino
 Manuscript Title: Hyperprogressive disease under anti-PD-1 rechallenge after a favorable response to initial anti-PD-1 treatment for non-small cell lung cancer: a case report
 Manuscript number (if known): TLCR-23-765-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u>None</u>	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u>None</u>	
3	Royalties or licenses	<u>None</u>	
4	Consulting fees	<u>None</u>	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> </u> None	
6	Payment for expert testimony	<u> </u> None	
7	Support for attending meetings and/or travel	<u> </u> None	
8	Patents planned, issued or pending	<u> </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> </u> None	
11	Stock or stock options	<u> </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> </u> None	
13	Other financial or non-financial interests	<u> </u> None	

Please summarize the above conflict of interest in the following box:

None

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Feb 12th, 2024
 Your Name: Motoyasu Kato
 Manuscript Title: Hyperprogressive disease under anti-PD-1 rechallenge after a favorable response to initial anti-PD-1 treatment for non-small cell lung cancer: a case report
 Manuscript number (if known): TLCR-23-765-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author’s relationships/activities/interests as they relate to the current manuscript only.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> </u> None	
6	Payment for expert testimony	<u> </u> None	
7	Support for attending meetings and/or travel	<u> </u> None	
8	Patents planned, issued or pending	<u> </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> </u> None	
11	Stock or stock options	<u> </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> </u> None	
13	Other financial or non-financial interests	<u> </u> None	

Please summarize the above conflict of interest in the following box:

None.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Feb 6th, 2024

Your Name: Antoshi Hattori

Manuscript Title: Hyperprogressive disease under anti-PD-1 rechallenge after a favorable response to initial anti-PD-1 treatment for non-small cell lung cancer: a case report

Manuscript number (if known): TLCR-23-765-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	___ None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	___ None	
3	Royalties or licenses	___ None	
4	Consulting fees	___ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> </u> None	
6	Payment for expert testimony	<u> </u> None	
7	Support for attending meetings and/or travel	<u> </u> None	
8	Patents planned, issued or pending	<u> </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> </u> None	
11	Stock or stock options	<u> </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> </u> None	
13	Other financial or non-financial interests	<u> </u> None	

Please summarize the above conflict of interest in the following box:

Please place an "X" next to the following statement to indicate your agreement:

 X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Feb 6th, 2024

Your Name: Naoko Shimada

Manuscript Title: Hyperprogressive disease under anti-PD-1 rechallenge after a favorable response to initial anti-PD-1 treatment for non-small cell lung cancer: a case report

Manuscript number (if known): TLCR-23-765-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<u> </u> None	
6	Payment for expert testimony	<u> </u> None	
7	Support for attending meetings and/or travel	<u> </u> None	
8	Patents planned, issued or pending	<u> </u> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<u> </u> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<u> </u> None	
11	Stock or stock options	<u> </u> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> </u> None	
13	Other financial or non-financial interests	<u> </u> None	

Please summarize the above conflict of interest in the following box:

None.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Feb 20th, 2024
 Your Name: Kenji Suzuki
 Manuscript Title: Hyperprogressive disease under anti-PD-1 rechallenge after a favorable response to initial anti-PD-1 treatment for non-small cell lung cancer: a case report
 Manuscript number (if known): TLCR-23-765-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<u> </u> <input checked="" type="checkbox"/> None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<u> </u> <input checked="" type="checkbox"/> None	
3	Royalties or licenses	<u> </u> <input checked="" type="checkbox"/> None	
4	Consulting fees	<u> </u> <input checked="" type="checkbox"/> None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> None	
		Ethicon Intuitive	
6	Payment for expert testimony	<input checked="" type="checkbox"/> None	
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None	
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None	
11	Stock or stock options	<input checked="" type="checkbox"/> None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

Kenji Suzuki received payment or honoraria for lectures, presentations, speaker bureaus from Ethicon, Intuitive.

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Feb 20th, 2024
 Your Name: Shigehisa Kitano
 Manuscript Title: Hyperprogressive disease under anti-PD-1 rechallenge after a favorable response to initial anti-PD-1 treatment for non-small cell lung cancer: a case report
 Manuscript number (if known): TLCR-23-765-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).		For all the research, all the payments were made to our institute and me.
		Ono Pharmaceutical	Research Grant (collaborative research and clinical trial)
		Eisai	Research Grant (collaborative research and clinical trial)
		Boehringer Ingelheim	Research Grant (collaborative research and clinical trial)
		Astellas Pharma	Research Grant (collaborative research and clinical trial)
		Daiichi Sankyo	Research Grant (collaborative research and clinical trial)
	Takara Bio	Research Grant (collaborative research)	

		MSD Chugai Pfizer Astra Zeneca Incyte, Abbvie, Takeda GSK LOXO/Lilly	Research Grant (clinical trial) Research Grant (collaborative research and clinical trial) Research Grant (clinical trial)
3	Royalties or licenses	None	
4	Consulting fees	Ono Pharmaceutical Chugai Astra Zeneca Sumitomo Pharma GSK Rakuten Meidical ImmuniT Research United Immunity Astellas Pharma	Scientific Advice, payments were made to me. Scientific Advice, payments were made to me.
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Ono Pharmaceutical Bristol-Myers Squibb Astra Zeneca Chugai MSD Merck KGaA	Lecture fee, payments were made to me. Lecture fee, payments were made to me.
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	

12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<u> </u> None	
13	Other financial or non-financial interests	<u> </u> None	

Please summarize the above conflict of interest in the following box:

I have no COI for this study.
 Outside of submitted work, potential COIs are listed in the table above.
 Shigehisa Kitano received grants from Ono Pharmaceutical, Eisai, Boehringer Ingelheim, Astellas Pharma, Daiichi Sankyo, Takara Bio, MSD Chugai, Pfizer, Astra Zeneca, Incyte, Abbvie, Takeda, GSK, LOXO/Lilly and consulting fees from Ono Pharmaceutical, Chugai, Astra Zeneca, Sumitomo Pharma, GSK, Rakuten Meidical, ImmuniT Research, United Immunity, Astellas Pharma. I received lecture fee from Ono Pharmaceutical, Bristol-Myers Squibb, Astra Zeneca, Chugai, MSD, Merck KGaA.

Please place an "X" next to the following statement to indicate your agreement:

 X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: Feb 20th, 2024

Your Name: [KAZUHISA TAKAHASHI]

Manuscript Title: [Hyperprogressive disease under anti-PD-1 rechallenge after a favorable response to initial anti-PD-1 treatment for non-small cell lung cancer: a case report]

Manuscript Number (if known): TLCR-23-765-R2

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None	
			Click the tab key to add additional rows.
Time frame: past 36 months			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)																																										
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None <table border="1" data-bbox="384 338 946 1240"> <tr><td>Chugai Pharmaceutical Co., Ltd.</td><td>Grants</td></tr> <tr><td>Nippon Boehringer Ingelheim Co., Ltd.</td><td>Grants</td></tr> <tr><td>NIPPON SHINYAKU CO., LTD.</td><td>Grants</td></tr> <tr><td>TSUMURA & CO.</td><td>Grants</td></tr> <tr><td>Pfizer Inc.</td><td>Grants</td></tr> <tr><td>TAIHO PHARMACEUTICAL CO., LTD.</td><td>Grants</td></tr> <tr><td>KYORIN Pharmaceutical Co., LTD</td><td>Grants</td></tr> <tr><td>TEIJIN PHARMA LIMITED</td><td>Grants</td></tr> <tr><td>Sanofi K. K.</td><td>Grants</td></tr> <tr><td>ONO PHARMACEUTICAL CO., LTD.</td><td>Grants</td></tr> <tr><td>Novartis Pharma K. K.</td><td>Grants</td></tr> <tr><td>SHIONOGI & CO., LTD.</td><td>Grants</td></tr> <tr><td></td><td></td></tr> <tr><td>Eli Lilly Japan K. K.</td><td>Grants</td></tr> <tr><td>Bayer Yakuhin, Ltd</td><td>Grants</td></tr> <tr><td>DAIICHI SANKYO Co., LTD.</td><td>Grants</td></tr> <tr><td>NIPRO PHARMA CORPORATION</td><td>Grants</td></tr> <tr><td>Asahi Kasei Pharma Corporation</td><td>Grants</td></tr> <tr><td>Nippon Kayaku Co.,Ltd.</td><td>Grants</td></tr> <tr><td>Takeda Pharmaceutical Company Limited.</td><td>Grants</td></tr> <tr><td>Kyowa Kirin Co., Ltd.</td><td>Grants</td></tr> </table>	Chugai Pharmaceutical Co., Ltd.	Grants	Nippon Boehringer Ingelheim Co., Ltd.	Grants	NIPPON SHINYAKU CO., LTD.	Grants	TSUMURA & CO.	Grants	Pfizer Inc.	Grants	TAIHO PHARMACEUTICAL CO., LTD.	Grants	KYORIN Pharmaceutical Co., LTD	Grants	TEIJIN PHARMA LIMITED	Grants	Sanofi K. K.	Grants	ONO PHARMACEUTICAL CO., LTD.	Grants	Novartis Pharma K. K.	Grants	SHIONOGI & CO., LTD.	Grants			Eli Lilly Japan K. K.	Grants	Bayer Yakuhin, Ltd	Grants	DAIICHI SANKYO Co., LTD.	Grants	NIPRO PHARMA CORPORATION	Grants	Asahi Kasei Pharma Corporation	Grants	Nippon Kayaku Co.,Ltd.	Grants	Takeda Pharmaceutical Company Limited.	Grants	Kyowa Kirin Co., Ltd.	Grants	
Chugai Pharmaceutical Co., Ltd.	Grants																																												
Nippon Boehringer Ingelheim Co., Ltd.	Grants																																												
NIPPON SHINYAKU CO., LTD.	Grants																																												
TSUMURA & CO.	Grants																																												
Pfizer Inc.	Grants																																												
TAIHO PHARMACEUTICAL CO., LTD.	Grants																																												
KYORIN Pharmaceutical Co., LTD	Grants																																												
TEIJIN PHARMA LIMITED	Grants																																												
Sanofi K. K.	Grants																																												
ONO PHARMACEUTICAL CO., LTD.	Grants																																												
Novartis Pharma K. K.	Grants																																												
SHIONOGI & CO., LTD.	Grants																																												
Eli Lilly Japan K. K.	Grants																																												
Bayer Yakuhin, Ltd	Grants																																												
DAIICHI SANKYO Co., LTD.	Grants																																												
NIPRO PHARMA CORPORATION	Grants																																												
Asahi Kasei Pharma Corporation	Grants																																												
Nippon Kayaku Co.,Ltd.	Grants																																												
Takeda Pharmaceutical Company Limited.	Grants																																												
Kyowa Kirin Co., Ltd.	Grants																																												
3	Royalties or licenses	<input checked="" type="checkbox"/> None <table border="1" data-bbox="384 1346 946 1487"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>																																											
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1" data-bbox="384 1585 946 1765"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>																																											
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	<input type="checkbox"/> None <table border="1" data-bbox="384 1861 946 2123"> <tr><td>Chugai Pharmaceutical Co., Ltd.</td><td>honoraria for speaking at sponsored meetings</td></tr> <tr><td>Nippon Boehringer Ingelheim Co., Ltd.</td><td>honoraria for speaking at sponsored meetings</td></tr> <tr><td>MSD K. K.</td><td>honoraria for speaking at sponsored meetings</td></tr> <tr><td>Pfizer Inc.</td><td>honoraria for speaking at sponsored meetings</td></tr> <tr><td>AstraZeneca K. K.</td><td>honoraria for speaking at sponsored meetings</td></tr> <tr><td>TAIHO PHARMACEUTICAL CO., LTD.</td><td>honoraria for speaking at sponsored meetings</td></tr> </table>	Chugai Pharmaceutical Co., Ltd.	honoraria for speaking at sponsored meetings	Nippon Boehringer Ingelheim Co., Ltd.	honoraria for speaking at sponsored meetings	MSD K. K.	honoraria for speaking at sponsored meetings	Pfizer Inc.	honoraria for speaking at sponsored meetings	AstraZeneca K. K.	honoraria for speaking at sponsored meetings	TAIHO PHARMACEUTICAL CO., LTD.	honoraria for speaking at sponsored meetings																															
Chugai Pharmaceutical Co., Ltd.	honoraria for speaking at sponsored meetings																																												
Nippon Boehringer Ingelheim Co., Ltd.	honoraria for speaking at sponsored meetings																																												
MSD K. K.	honoraria for speaking at sponsored meetings																																												
Pfizer Inc.	honoraria for speaking at sponsored meetings																																												
AstraZeneca K. K.	honoraria for speaking at sponsored meetings																																												
TAIHO PHARMACEUTICAL CO., LTD.	honoraria for speaking at sponsored meetings																																												

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
educational events	KYORIN Pharmaceutical Co., LTD	honoraria for speaking at sponsored meetings						
	Merck Biopharma Co., Ltd.	honoraria for speaking at sponsored meetings						
	ONO PHARMACEUTICAL CO., LTD.	honoraria for speaking at sponsored meetings						
	Nippon Kayaku Co.,Ltd.	honoraria for speaking at sponsored meetings						
	Novartis Pharma K. K.	honoraria for speaking at sponsored meetings						
	Eli Lilly Japan K. K.	honoraria for speaking at sponsored meetings						
	Sumitomo Dainippon Pharma Co., Ltd.	honoraria for speaking at sponsored meetings						
	Bristol-Myers K. K.	honoraria for speaking at sponsored meetings						
	Meiji Seika Pharma Co., Ltd.	honoraria for speaking at sponsored meetings						
	Takeda Pharmaceutical Company Limited.	honoraria for speaking at sponsored meetings						
	Viartis Inc	honoraria for speaking at sponsored meetings						
	Janssen Pharmaceutical K.K.	honoraria for speaking at sponsored meetings						
	Abbott Japan LLC	honoraria for speaking at sponsored meetings						
	Thermo Fisher Scientific Inc.	honoraria for speaking at sponsored meetings						
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						
8	Patents planned, issued or pending	<input type="checkbox"/> None <table border="1"> <tr> <td>METHOD FOR DETECTING CELLS</td> <td>Issued: P6840330/2021.3.10</td> </tr> <tr> <td>THE METHOD FOR DETECTING CIRCULATING TUMOR CELLS USING VIRUS</td> <td>Pending</td> </tr> <tr> <td>CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma</td> <td>Pending</td> </tr> </table>	METHOD FOR DETECTING CELLS	Issued: P6840330/2021.3.10	THE METHOD FOR DETECTING CIRCULATING TUMOR CELLS USING VIRUS	Pending	CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma	Pending
METHOD FOR DETECTING CELLS	Issued: P6840330/2021.3.10							
THE METHOD FOR DETECTING CIRCULATING TUMOR CELLS USING VIRUS	Pending							
CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma	Pending							
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						
10	Leadership or fiduciary role in other board, society,	<input type="checkbox"/> None <table border="1"> <tr> <td>The Japan Lung Cancer Society</td> <td>Board of Director</td> </tr> <tr> <td>The Japanese Respiratory Society</td> <td>Board of Director</td> </tr> </table>	The Japan Lung Cancer Society	Board of Director	The Japanese Respiratory Society	Board of Director		
The Japan Lung Cancer Society	Board of Director							
The Japanese Respiratory Society	Board of Director							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	committee or advocacy group, paid or unpaid		
1 1	Stock or stock options	<input checked="" type="checkbox"/> None	
1 2	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
1 3	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	

Please summarize the above conflict of interest in the following box:

KAZUHISA TAKAHASHI received grants from Chugai Pharmaceutical Co., Ltd, Nippon Boehringer Ingelheim Co., Ltd, NIPPON SHINYAKU CO., LTD, TSUMURA & CO, Pfizer Inc, TAIHO, PHARMACEUTICAL CO., LTD, KYORIN Pharmaceutical Co., LTD, TEIJIN PHARMA LIMITED, Sanofi K. K., ONO PHARMACEUTICAL CO., LTD, Novartis Pharma K. K, SHIONOGI & CO., LTD, Eli Lilly Japan K. K., Bayer Yakuhin, Ltd, DAIICHI SANKYO Co, LTD, NIPRO PHARMA CORPORATION, Asahi Kasei Pharma Corporation, Nippon Kayaku Co.,Ltd, Takeda, Pharmaceutical Company Limited, Kyowa Kirin Co., Ltd.

KAZUHISA TAKAHASHI received honoraria for speaking at sponsored meetings from Chugai Pharmaceutical Co., Ltd, Nippon Boehringer Ingelheim Co., Ltd, MSD K. K, Pfizer Inc, AstraZeneca K. K, TAIHO PHARMACEUTICAL CO., LTD, KYORIN Pharmaceutical Co., LTD, Merck Biopharma Co., Ltd, ONO PHARMACEUTICAL CO., LTD, Nippon Kayaku Co.,Ltd, Novartis Pharma K. K, Eli Lilly Japan K. K, Sumitomo Dainippon Pharma Co., Ltd, Bristol-Myers K. K, Meiji Seika Pharma Co, Ltd., Takeda Pharmaceutical Company Limited, Viatrix Inc, Janssen Pharmaceutical K.K, Abbott Japan LLC, Thermo Fisher Scientific Inc.

KAZUHISA TAKAHASHI obtains patents “METHOD FOR DETECTING CELLS” (issued), “THE METHOD FOR DETECTING CIRCULATING TUMOR CELLS USING VIRUS” (pending), and “CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma” (pending).

KAZUHISA TAKAHASHI serves as Board of Director in The Japan Lung Cancer Society and The Japanese Respiratory Society.

Please place an “X” next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.